Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Haruhiko Fukuda
With
Ministry of Health, Labour and Welfare, Japan
Preoperative chemotherapy has substantial theoretical advantage. Several controlled trials are under way in early stage (clinical stage IB-II) nonsmall cell lung cancer (NSCLC). In each trial, platinum-based doublet chemotherapy is employed. Although platinum-based doublet is the treatment of choice for advanced NSCLC, risk/benefit balance might well be different in earlier stages. There have been no prospective randomized trials to choose an optimal preoperative chemotherapy in early stage NSCLC.
Comparison: Preoperative cisplatin-docetaxel combination versus docetaxel monotherapy in clinical stage IB/II NSCLC.
Age
20–74
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Newly diagnosed, pathologically documented NSCLC
Clinical stages IB (T2N0M0), IIA (T1N1M0) or IIB (T2N1M0 or T3N0M0)
Ages: 15-74 years old
ECOG performance status 0 or 1
Measurable disease
Ample organ function
Signed informed consent
You may not be if
Invasion to the first rib or more superior chest wall
Metastasis to, or involvement of, mediastinal node
Active concomitant malignancy
Unstable angina, recent myocardial infarction, or heart failure